The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BTTC | N/A | N/A | N/A | -86% |
| S&P | +14.11% | +87.98% | +13.46% | +3% |
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
No news articles found for Black Titan.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$0.80M | -5.2% |
| EBITDA | -$0.78M | -3.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.96M | -42.5% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -96.62% | -10.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.76M | -9.5% |
| Operating Free Cash Flow | -$0.75M | -8.8% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Sales | 34.85 | 70.20 | 1272.74 | - | |
| Enterprise Value to EBITDA | -0.23 | -2.40 | -2.54 | -6.10 | 224.37% |
| Return on Equity | -103.6% | -105.7% | -82.7% | -109.1% | 5.30% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.